Since you asked the question, I'll venture an answer.
A) Your fundamental premise that ResappDx is "a similar medical device" is in my opinion quite wrong. ResappDx is a service. Supplying the service requires no manufacture or delivery of any hardware.
B) The stethoscope is absolutely not competitive with ResappDx, and I believe you know that even though you keep asserting it. ResappDx competes with chest imaging, which is costly and often involves exposure to X-rays, and with bacteriology, which is time consuming and delays the commencement of treatment.
C) As a service ResappDx attracts a fee-per-use rather than a once-off-and that's all price. Also, as a digital-only service the unit cost to serve is close to zero; no need for components, manufacture, warranty or logistics.
D) ResappDx is ready to use in its present form. The clinical studies being conducted in Australia and the US are using the finished end product (inasmuch as any software is ever "finished").
On the question of preliminary results, it's hard to judge. The previous US trial failed because of an operational fluff that effectively prevented the product from even being tested. So there isn't anything really for ResappDx to compare against Mente Autism's glowing interim report, which was very pleasing indeed.
Thinking at a higher level, I'm a little confused as to why you're so exercised about the differential. It's not as if Resapp is somehow suppressing Neurotech. The market values each as is has. In the medium term we'll discover how well-valued each stock is when we have earnings-per-share figures, and hopefully even dividends!
My prediction for this stock in three months (in the expectation that the results reflect the interim report) is $0.35 to $0.45. On approval from the FDA some time next year I guess $0.60 to $0.75.
NTI Price at posting:
20.0¢ Sentiment: Hold Disclosure: Held
